Medical Robotics Market Size, Share, Growth & Forecast 2026–2035

Medical Robotics encompasses computer-controlled systems that position, guide or actuate instruments and devices in clinical care. This report covers four product families — surgical robotic systems, rehabilitation robotic systems, hospital and pharmacy automation robots, and non-invasive radiosurgery robots — together with the instruments, accessories and services sold around them, across orthopedic, neurological, urologic, gynecologic, cardiac and general surgical use.

The value chain runs in three tiers. Foundational platform providers — Intuitive Surgical, Medtronic and Stryker, with Johnson & Johnson MedTech and Zimmer Biomet — own the largest installed bases and the per-procedure instrument revenue that follows them. Specialist developers, including CMR Surgical, Medicaroid and MicroPort MedBot, compete with modular, lower-cost or telesurgery-ready systems. Application-layer specialists such as Omnicell, Swisslog Healthcare and Lifeward apply robotics to pharmacy logistics and rehabilitation.

For hospital buyers and investors, the useful question isn't whether robotics keeps growing — it's which platforms, specialties and care settings capture the value. This report answers that with sub-segment data across four segmentation dimensions and country-level forecasts for 35+ geographies.

According to NHS England, as reported by Digital Health, June 2025, NHS England projects that around 500,000 robot-assisted operations a year will be performed in England by 2035, a demand signal that frames hospital robot procurement and surgeon training plans across the forecast period.

Moon Surgical's ScoPilot, cleared by the FDA in July 2025, uses AI running on NVIDIA's Holoscan platform to position the laparoscope on the Maestro system, one of the first examples of physical AI handling a routine operating-room task. The same shift is under way at larger OEMs: Johnson & Johnson MedTech is building AI features with NVIDIA, and Zimmer Biomet acquired Monogram for its autonomous orthopedic robotics.

For hospitals, AI changes what a robot is worth: a system that captures procedure data, automates camera work and supports planning saves staff time and narrows variation between surgeons. It also moves vendor revenue toward software and services, the fastest-growing component in this report at a 25.34% CAGR through 2035. Expect AI-assisted planning and camera control to become a standard tender requirement before 2030.

Surgical robotic systems hold 43.3% of 2025 revenue (USD 4,434.8 Mn), a lead built on installed soft-tissue and orthopedic platforms that pull through instrument sales on every case. Rehabilitation robotic systems are the fastest-growing product type at a 23.05% CAGR, rising from USD 2,239.7 Mn in 2025 to USD 17,831.1 Mn by 2035 as payers start covering exoskeletons and stroke and spinal-cord programs scale. Wandercraft's October 2026 acquisition of Ekso Bionics shows how quickly that category is consolidating. Hospital and pharmacy automation robots (20.5%) and non-invasive radiosurgery robots (14.3%) grow more slowly. By 2035, surgical and rehabilitation systems together account for roughly four-fifths of market value.

Orthopedic surgery is the dominant application at 29.7% of 2025 revenue (USD 3,041.8 Mn), anchored by knee and hip robotics with high, predictable procedure volumes. Neurology is the fastest-growing application at a 24.62% CAGR, from USD 1,776.7 Mn in 2025 to USD 16,056.4 Mn by 2035, as spine and cranial navigation robots spread beyond academic centers. Urology (16.1%) and gynecology (14.0%) follow, and both are where new soft-tissue entrants are aiming first: Medtronic's Hugo cleared for urology in December 2025 and filed for gynecology in June 2026. Orthopedics keeps the largest base, but its 9.02% CAGR means neurology overtakes it in value before 2035.

Hospitals & clinics are the dominant end user at 46.2% of 2025 revenue (USD 4,730.5 Mn), because they hold the capital budgets, operating rooms and credentialing programs robotic surgery requires. Ambulatory surgical centers are the fastest-growing end user at a 23.28% CAGR, climbing from USD 1,918.6 Mn in 2025 to USD 15,555.1 Mn by 2035 as compact and handheld systems make outpatient robotics affordable. Distalmotion's USD 150 Mn raise in November 2025 to push its Dexter robot into U.S. outpatient settings is a direct bet on that shift. Rehabilitation centers hold 20.7% and academic and research institutes 14.4%. Expect ASCs to approach a third of end-user revenue by the end of the forecast horizon.

Instruments & accessories are the dominant component at 54.0% of 2025 revenue (USD 5,531.4 Mn), since every robotic procedure consumes proprietary, often single-use tools. Services are the fastest-growing component at a 25.34% CAGR, expanding from USD 1,552.3 Mn in 2025 to USD 14,853.7 Mn by 2035 as installed fleets age into maintenance, software and training contracts. Intuitive Surgical's January 2026 guidance of 13–15% worldwide da Vinci procedure growth shows why recurring revenue outruns hardware. Systems hold 30.8% of revenue but grow at just 9.73% a year. The volume-value split is clear: placements open the account, procedures and service contracts fill it.

Vectomat Insights estimates 19,740 medical robotic systems were shipped worldwide in 2025. Volume and value point in different directions. Rehabilitation systems lead on units at 45.1%, with hospital and pharmacy automation robots at 38.5%, yet surgical robotic systems lead on revenue with only 14.9% of units. That gap reflects price: surgical platforms average about USD 1.5 Mn of segment revenue per system shipped, against roughly USD 0.25 Mn for rehabilitation units and about USD 5.0 Mn for the 290 radiosurgery systems. The blended figure is about USD 0.52 Mn per system.

Medical robotics is a concentrated market at the top and a fragmented one beneath it. A handful of platform owners — Intuitive Surgical in soft tissue, Stryker and Zimmer Biomet in orthopedics — control the largest installed bases, and their recurring instrument revenue makes that position hard to dislodge. The challenge now comes from well-funded entrants: Medtronic's Hugo, CMR Surgical's Versius Plus and Johnson & Johnson MedTech's Ottava all reached the U.S. market within eight months of each other. Asian OEMs such as Medicaroid and MicroPort MedBot compete on price and telesurgery, while rehabilitation and pharmacy automation remain specialist arenas. Key players include Intuitive Surgical, Medtronic, Stryker, Johnson & Johnson MedTech, Zimmer Biomet, CMR Surgical, Medicaroid, MicroPort MedBot, SS Innovations, Distalmotion, Accuray, Wandercraft, Lifeward, Omnicell, Swisslog Healthcare, among others.

Strategic activity clusters around three moves: alliances and acquisitions that buy a missing specialty, as with Stryker's USD 400 Mn CMR alliance and Zimmer Biomet's Monogram deal; regulatory pushes into new geographies, led by Medicaroid's European CE mark; and lower-cost or telesurgery-capable platforms aimed at hospitals priced out of incumbent systems. Expect further consolidation among sub-scale exoskeleton and soft-tissue vendors through 2030.

Component and Subsystem Supply — Precision actuators, motors, sensors, 3D vision optics and computing hardware feed every platform, and much of this stage sits with industrial robotics and semiconductor suppliers rather than medical OEMs. Lead times for high-precision drives and custom optics set the pace of system output, and tariff exposure on cross-border component flows became a margin issue for U.S. OEMs in 2025. Key Players: KUKA Group (parent of Swisslog Healthcare), NVIDIA (AI compute), Kawasaki Heavy Industries (Medicaroid co-owner).

Robotic Platform Design and Manufacturing — Platform OEMs integrate hardware, software, instruments and regulatory files into a cleared system, and they capture most of the value through proprietary instruments sold per procedure. This is where clearance timelines and clinical evidence decide market entry, as the December 2025 FDA decisions for Hugo and Versius Plus showed. Key Players: Intuitive Surgical, Medtronic, Stryker, CMR Surgical, Medicaroid, MicroPort MedBot.

Clinical Deployment, Training and Service — Hospitals, ambulatory surgical centers and rehabilitation clinics install the systems, credential surgeons and therapists, and buy multi-year service contracts. Utilisation drives the economics here: an idle robot is a stranded capital asset, so OEM training programs and uptime guarantees carry as much weight in procurement as list price. Key Players: Omnicell, Lifeward, Wandercraft, hospital robotic surgery programs such as Cleveland Clinic.

North America leads the Global Medical Robotics market with a 40.0% share, while Asia Pacific is the fastest-growing region. The split is structural: North America monetises a mature installed base through procedures and service, whereas Asia Pacific is adding new systems, new domestic platforms and new reimbursement codes at the same time.

North America holds 40.0% of the 2025 Medical Robotics market (USD 4,096.8 Mn), the largest share of any region, built on dense hospital robotic programs and the deepest installed base in soft-tissue and orthopedic surgery. The United States alone accounts for USD 3,047.7 Mn and is forecast to grow at a 16.1% CAGR to USD 13,561.1 Mn by 2035. Competition is the new variable: Medtronic's Hugo won FDA clearance in December 2025, and Cleveland Clinic performed the first U.S. Hugo case in February 2026. Canada and Mexico add smaller, hospital-led demand. The principal challenge is payer volatility, after expiring ACA subsidies slowed U.S. procedure growth in mid-2026. The U.S. still adds more absolute value than any other country through 2035, at USD 10,513.4 Mn.

Europe holds 25.7% of 2025 global revenue (USD 2,632.1 Mn). Germany leads the region at USD 755.7 Mn and is forecast to grow at a 15.5% CAGR to USD 3,192.8 Mn by 2035, backed by a large hospital base and early adoption of orthopedic robotics. The U.K. is the policy story: NHS England projects around 500,000 robot-assisted operations a year by 2035. France and BENELUX add steady demand, and Medicaroid's July 2026 CE mark for hinotori brings a Japanese platform into European tenders. The region's principal challenge is EU MDR certification capacity, which slows new-system approvals. Structurally, Europe is a multi-vendor tender market rather than a single-platform one.

Asia Pacific is the fastest-growing of the six VMI regions and holds 20.9% of 2025 revenue (USD 2,140.5 Mn). South Korea is the highlighted country, at USD 412.0 Mn in 2025 and a forecast 19.4% CAGR to USD 2,426.3 Mn by 2035, the highest growth rate of any tracked country. Japan is larger at USD 552.3 Mn, growing at 17.8%, with Medicaroid's hinotori gaining domestic indications. China set national pricing items for robot-assisted surgery in May 2025, and MicroPort MedBot's Toumai passed 200 global commercial orders in February 2026; India adds low-cost demand through SS Innovations. Reimbursement outside Japan and South Korea remains uneven. Expect Asia Pacific's share to climb steadily through 2035 as domestic platforms scale.

Latin America accounts for 6.6% of 2025 revenue (USD 676.0 Mn), with Brazil the clear regional leader. Robotic surgery is now reaching Brazil's public SUS system, which opened its first robotics training and research center in November 2025, while private hospital groups drive most placements. Argentina, Colombia and Chile add smaller, private-sector demand. Currency swings raise the effective cost of imported systems, and trained robotic surgeons remain concentrated in a few large cities. That makes training capacity, not demand, the region's binding constraint, at 6.6% of global value.

The Middle East holds 4.8% of 2025 global revenue (USD 491.6 Mn), led by GCC hospital investment in Saudi Arabia and the UAE. King Faisal Specialist Hospital & Research Centre in Riyadh has built a world-first record in robotic cardiac surgery, and Cleveland Clinic Abu Dhabi performed the first UAE-to-Pakistan remote robotic kidney telesurgery in February 2026. Israel adds a strong medtech development base. The principal challenge is a small surgeon training pipeline relative to the pace of hospital spending. Cleveland Clinic Abu Dhabi's cross-border telesurgery case is the clearest signal of where the region wants to compete.

Africa accounts for 2.0% of 2025 revenue (USD 204.8 Mn), with South Africa and Egypt the leading markets. Tygerberg Hospital in the Western Cape became the first South African government hospital to perform robotic surgery, and the University of the Free State introduced a new surgical robotic system in March 2025. Egypt's Ain Shams University runs a robotic surgery program, and Nigeria recorded early robot-assisted cases in private hospitals. Capital affordability is the region's main restraint, and installed systems remain concentrated in a handful of teaching hospitals. Robotics in Africa is, for now, a teaching-hospital technology rather than a district-hospital one.

Regulatory-approval program — The FDA's September 2026 draft guidance on premarket submissions for robotically-assisted surgical devices sets clearer evidence expectations for new platforms, following a wave of clearances that included Hugo and Versius Plus in December 2025. (FDA draft guidance: Robotically-Assisted Surgical Devices — Premarket Submissions)

Reimbursement/funding initiative — China's National Healthcare Security Administration issued pricing guidelines for 28 medical services in May 2025, creating price items for surgical-robot assistance that give hospitals a billing route for robotic procedures. (NHSA pricing guidelines for 28 medical services)

Public health capacity program — NHS England projects around 500,000 robot-assisted operations a year by 2035, a public-sector demand signal that is pushing trusts to plan multi-year robot procurement and surgeon training.

Healthcare transformation investment — Saudi Arabia's health sector transformation under Vision 2030 funds advanced surgical capability at flagship hospitals, which is why centers such as King Faisal Specialist Hospital & Research Centre are early adopters of robotic cardiac surgery. (Saudi Vision 2030 Health Sector Transformation Program)

Recent activity in medical robotics is dominated by regulatory clearances for new soft-tissue platforms and by orthopedic majors buying their way into autonomy and soft tissue.